Comments on: Trends Update — Comparative Effectiveness and Personalized Medicine: Genetic Test Identifies Patient Subpopulation for Benefit, Avoids Wasted Money and Time for Others on Erbitux, Vectibix

By: Biotech Trends Update: A Personalized Critique of Comparative Effectiveness Misses the Mark « The Cross-Border Biotech Blog

Thu, 18 Mar 2010 11:03:30 +0000

[...] blog has noted on many occasions, CER is at its best when coupled with personalized medicine. This post about KRAS genotyping is a great example. This point is not lost on the Obama administration, which is aware of and sensitive to the need [...]

By: Biotech Trends Update: Costs Savings from Personalized Medicine Sought by PBMs, Employers, Pharma Face Legal and Privacy Hurdles « The Cross-Border Biotech Blog

Thu, 04 Feb 2010 18:22:47 +0000

[...] approaches to treatment have the potential to benefit all participants in the healthcare system, as the KRAS-Erbitux story has proven. As Procter & Gamble said when investing in Navigenics’ funding round this week, [...]

By: Top 10 Cross-Border Biotech Blog Posts of 2009 « The Cross-Border Biotech Blog

Sun, 03 Jan 2010 22:21:15 +0000

[...] Comparative Effectiveness and Personalized Medicine (and another post in that series on KRAS genotyping) [...]

By: Preventing Bias in Comparative Effectiveness Research « The Cross-Border Biotech Blog

Tue, 20 Oct 2009 18:51:13 +0000

[...] seems like another great example of personalized medicine informing a comparative effectiveness decision. But, as the In Vivo Blog [...]

By: Trends Update — “Personalized Effectiveness”: Amgen Gets Prospective Data to Back KRAS-Vectibix Plan « The Cross-Border Biotech Blog

Tue, 11 Aug 2009 12:04:43 +0000

[...] 11, 2009 · Leave a Comment A few weeks ago, when the FDA changed the labeling on anti-EGFR drugs, Amgen was pretty enthusiastic about “avoiding unnecessary treatments in patients [with a [...]